Literature DB >> 23946674

Low-grade inflammation as trade-off causing chronic complex diseases.

Hiroyuki Koshiyama1.   

Abstract

Entities:  

Year:  2010        PMID: 23946674      PMCID: PMC3738487     

Source DB:  PubMed          Journal:  Jpn Clin Med        ISSN: 1179-6707


× No keyword cloud information.
Recently, it has been suggested that low-grade inflammation may underlie chronic complex diseases, such as diabetes, dyslipidemia, atheroslerosis, and metabolic syndrome.1,2 High-sensitivity C-reactive protein has been adopted as a biomarker.3–5 However, the site of low-grade inflammation has been of debate; whether it is the adipose tissue6 or other tissues such as the periodontal tissue.7 Evolutionary medicine can give us an ultimate cause (ie, “why”) of some disease rather than a proximate cause (ie, “how”).8,9 The key concept of evolutionary medicine is the “mismatch” between the selection pressure and the change of environment.8–13 Some phenotype, which is advantageous for humans against some conditions, can cause several diseases, as trade-off.8–13 Humans have been exposed to infections by helminthes and bacteria, both of which have contributed to develop innate immunity as a defense system.10,12 A proposed mechanism of an increase in allergy, termed the “hygiene hypothesis”, is that the appropriate exposure to helminthes early in life is essential to set up immunoregulatory pathways. Here I propose another paradigm from the viewpoint of evolutionary medicine why low-grade inflammation may underlie many complex diseases. The intestinal bacterial flora has evolved with humans, and they are now known to be fundamental to the development of the human innate immunity system. Increasing evidences have indicated that innate immunity may be associated with some disorders. For example, Toll-like receptors (TLRs) have been indicated in the pathogenesis of atherosclerosis. Free fatty acids, which are secreted from the adipose tissue, may act as an agonist of TLR4 and cause a pro-inflammatory response of macrophages,14 or oxidized LDL may be a ligand for TLR4.15 TLR5 knock-mouse has shown a change of gut microbiota as well as a phenotype of metabolic syndrome.16 Furthermore, very recently, it has been reported that carbohydrate-active enzymes are detected exclusively in intestinal flora of Japanese, which are derived from marine bacteria,17 suggesting a racial difference in co-evolution of intestinal flora and humans. Taken, together, it is possible that trade-offs of the innate immunity, which has evolved with intestinal flora, may underlie chronic complex diseases, such as obesity, atherosclerosis, or diabetes. A recent study has suggested that dark chocolate consumption changes gut microrbiota in humans.18 Since sweet taste is known to affect the secretion of glucagon-like peptide 1(GLP-1), one of the incretin hormones, it may be of interest to investigate whether incretin analog may change the gut microbiota.19
  13 in total

Review 1.  Inflammatory lipid mediators in adipocyte function and obesity.

Authors:  Abishek Iyer; David P Fairlie; Johannes B Prins; Bruce D Hammock; Lindsay Brown
Journal:  Nat Rev Endocrinol       Date:  2010-02       Impact factor: 43.330

2.  Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5.

Authors:  Matam Vijay-Kumar; Jesse D Aitken; Frederic A Carvalho; Tyler C Cullender; Simon Mwangi; Shanthi Srinivasan; Shanthi V Sitaraman; Rob Knight; Ruth E Ley; Andrew T Gewirtz
Journal:  Science       Date:  2010-03-04       Impact factor: 47.728

3.  Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.

Authors:  Paul M Ridker; Jean MacFadyen; Michael Cressman; Robert J Glynn
Journal:  J Am Coll Cardiol       Date:  2010-03-04       Impact factor: 24.094

4.  Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota.

Authors:  Jan-Hendrik Hehemann; Gaëlle Correc; Tristan Barbeyron; William Helbert; Mirjam Czjzek; Gurvan Michel
Journal:  Nature       Date:  2010-04-08       Impact factor: 49.962

5.  Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars.

Authors:  Hiroyuki Koshiyama; Ataru Taniguchi; Kiyoshi Tanaka; Shinji Kagimoto; Yoshio Fujioka; Kenichi Hirata; Yoshio Nakamura; Akane Iwakura; Kyoko Hara; Taizo Yamamoto; Akira Kuroe; Michihiro Ohya; Shimpei Fujimoto; Yoshiyuki Hamamoto; Sachiko Honjo; Hiroki Ikeda; Koichiro Nabe; Kinsuke Tsuda; Nobuya Inagaki; Yutaka Seino; Noriaki Kume
Journal:  J Atheroscler Thromb       Date:  2008-12-11       Impact factor: 4.928

Review 6.  Inflammation, C-reactive protein, and atherothrombosis.

Authors:  Paul M Ridker; Josh D Silvertown
Journal:  J Periodontol       Date:  2008-08       Impact factor: 6.993

7.  Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2.

Authors:  Yun Soo Bae; Jee Hyun Lee; Soo Ho Choi; Sunah Kim; Felicidad Almazan; Joseph L Witztum; Yury I Miller
Journal:  Circ Res       Date:  2008-12-18       Impact factor: 17.367

8.  Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects.

Authors:  Francois-Pierre J Martin; Serge Rezzi; Emma Peré-Trepat; Beate Kamlage; Sebastiano Collino; Edgar Leibold; Jürgen Kastler; Dietrich Rein; Laurent B Fay; Sunil Kochhar
Journal:  J Proteome Res       Date:  2009-12       Impact factor: 4.466

Review 9.  C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.

Authors:  Paul M Ridker
Journal:  J Am Coll Cardiol       Date:  2007-04-30       Impact factor: 24.094

10.  Species-specific actions of incretin: from the evolutionary perspective.

Authors:  Yukiko Kawasaki; Yoshiyuki Hamamoto; Hiroyuki Koshiyama
Journal:  Jpn Clin Med       Date:  2010-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.